Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dividend investing for retirement -- Ignore unavailable to you. Want to Upgrade?

To: the traveler who wrote (16620)	8/12/2013 10:50:07 AM
From: Steve Felix	Read Replies (2) \| Respond to of 34328

Analysts earning reductions: S&P KEEPS BUY RECOMMENDATON ON UNITS OF CALUMET SPECIALTY PRODUCTS (S&P Capital IQ) We keep our 12-month target price of $39, based on a 9.2X multiple of enterprise value to our '14 EBITDA forecast, higher than the refining peer average. Based on Q2 results, a higher unit count, and lower margins, we reduce our '13 earnings per unit estimate to $2.26 from $3.23, and '14's to $2.67 from $2.95. Adjusted Q2 earnings per unit of $0.11, vs. $1.42, was below our $0.90 estimate, reflecting lower than expected margins, higher than expected renewable credit expenses and a higher unit count. We expect distributions per unit to increase 13.4% to $2.745 in '13. You can read their transcript here and decide what you think of growth down the line: seekingalpha.com I have another order for 50 at 28.52.